[Results of the treatment of patients with atypical sarcoidosis of the respiratory organs].
Identifieur interne : 000141 ( Ncbi/Merge ); précédent : 000140; suivant : 000142[Results of the treatment of patients with atypical sarcoidosis of the respiratory organs].
Auteurs : M V TeriaevaSource :
- Problemy tuberkuleza [ 0032-9533 ] ; 1990.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Anti-inflammatoires (administration et posologie), Chloroquine (administration et posologie), Chloroquine (analogues et dérivés), Femelle, Humains, Lymphadénite (), Lymphadénite (traitement médicamenteux), Maladies pulmonaires (), Maladies pulmonaires (imagerie diagnostique), Maladies pulmonaires (traitement médicamenteux), Mâle, Prednisolone (administration et posologie), Radiographie, Sarcoïdose (), Sarcoïdose (imagerie diagnostique), Sarcoïdose (traitement médicamenteux), Vitamine E (administration et posologie).
- MESH :
- administration et posologie : Anti-inflammatoires, Chloroquine, Prednisolone, Vitamine E.
- analogues et dérivés : Chloroquine.
- imagerie diagnostique : Maladies pulmonaires, Sarcoïdose.
- traitement médicamenteux : Lymphadénite, Maladies pulmonaires, Sarcoïdose.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Lymphadénite, Maladies pulmonaires, Mâle, Radiographie, Sarcoïdose.
English descriptors
- KwdEn :
- Adult, Anti-Inflammatory Agents (administration & dosage), Chloroquine (administration & dosage), Chloroquine (analogs & derivatives), Female, Humans, Lung Diseases (complications), Lung Diseases (diagnostic imaging), Lung Diseases (drug therapy), Lymphadenitis (complications), Lymphadenitis (drug therapy), Male, Middle Aged, Prednisolone (administration & dosage), Radiography, Sarcoidosis (complications), Sarcoidosis (diagnostic imaging), Sarcoidosis (drug therapy), Vitamin E (administration & dosage).
- MESH :
- chemical , administration & dosage : Anti-Inflammatory Agents, Chloroquine, Prednisolone, Vitamin E.
- chemical , analogs & derivatives : Chloroquine.
- complications : Lung Diseases, Lymphadenitis, Sarcoidosis.
- diagnostic imaging : Lung Diseases, Sarcoidosis.
- drug therapy : Lung Diseases, Lymphadenitis, Sarcoidosis.
- Adult, Female, Humans, Male, Middle Aged, Radiography.
Abstract
Efficacy of treatment, including its immediate and longterm outcomes, in 109 patients with atypical respiratory sarcoidosis were analysed. The treatment regimens were as follows: corticosteroid hormones supplemented by delagil and vitamin E, intermittent corticosteroid therapy, administration of long-acting++ corticosteroid hormones and treatment with presocyl, delagil and vitamin E. Due to the given treatment, a favourable clinical effect was achieved in 74.3% of the cases with the process remaining stable in 2.8% and recurrent development of the disease in 22.9%. Persistent favourable outcomes in a distant future were registered in 82.9%, stable process--in 3.9%, and progression with aggravation and relapses--in 13.2% of the patients.
PubMed: 2084689
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000560
- to stream PubMed, to step Curation: 000560
- to stream PubMed, to step Checkpoint: 000529
Links to Exploration step
pubmed:2084689Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Results of the treatment of patients with atypical sarcoidosis of the respiratory organs].</title><author><name sortKey="Teriaeva, M V" sort="Teriaeva, M V" uniqKey="Teriaeva M" first="M V" last="Teriaeva">M V Teriaeva</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1990">1990</date><idno type="RBID">pubmed:2084689</idno><idno type="pmid">2084689</idno><idno type="wicri:Area/PubMed/Corpus">000560</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000560</idno><idno type="wicri:Area/PubMed/Curation">000560</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000560</idno><idno type="wicri:Area/PubMed/Checkpoint">000529</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000529</idno><idno type="wicri:Area/Ncbi/Merge">000141</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Results of the treatment of patients with atypical sarcoidosis of the respiratory organs].</title><author><name sortKey="Teriaeva, M V" sort="Teriaeva, M V" uniqKey="Teriaeva M" first="M V" last="Teriaeva">M V Teriaeva</name></author></analytic><series><title level="j">Problemy tuberkuleza</title><idno type="ISSN">0032-9533</idno><imprint><date when="1990" type="published">1990</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Anti-Inflammatory Agents (administration & dosage)</term><term>Chloroquine (administration & dosage)</term><term>Chloroquine (analogs & derivatives)</term><term>Female</term><term>Humans</term><term>Lung Diseases (complications)</term><term>Lung Diseases (diagnostic imaging)</term><term>Lung Diseases (drug therapy)</term><term>Lymphadenitis (complications)</term><term>Lymphadenitis (drug therapy)</term><term>Male</term><term>Middle Aged</term><term>Prednisolone (administration & dosage)</term><term>Radiography</term><term>Sarcoidosis (complications)</term><term>Sarcoidosis (diagnostic imaging)</term><term>Sarcoidosis (drug therapy)</term><term>Vitamin E (administration & dosage)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anti-inflammatoires (administration et posologie)</term><term>Chloroquine (administration et posologie)</term><term>Chloroquine (analogues et dérivés)</term><term>Femelle</term><term>Humains</term><term>Lymphadénite ()</term><term>Lymphadénite (traitement médicamenteux)</term><term>Maladies pulmonaires ()</term><term>Maladies pulmonaires (imagerie diagnostique)</term><term>Maladies pulmonaires (traitement médicamenteux)</term><term>Mâle</term><term>Prednisolone (administration et posologie)</term><term>Radiographie</term><term>Sarcoïdose ()</term><term>Sarcoïdose (imagerie diagnostique)</term><term>Sarcoïdose (traitement médicamenteux)</term><term>Vitamine E (administration et posologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Inflammatory Agents</term><term>Chloroquine</term><term>Prednisolone</term><term>Vitamin E</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Chloroquine</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anti-inflammatoires</term><term>Chloroquine</term><term>Prednisolone</term><term>Vitamine E</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Chloroquine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Lung Diseases</term><term>Lymphadenitis</term><term>Sarcoidosis</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Lung Diseases</term><term>Sarcoidosis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lung Diseases</term><term>Lymphadenitis</term><term>Sarcoidosis</term></keywords><keywords scheme="MESH" qualifier="imagerie diagnostique" xml:lang="fr"><term>Maladies pulmonaires</term><term>Sarcoïdose</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Lymphadénite</term><term>Maladies pulmonaires</term><term>Sarcoïdose</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Radiography</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Lymphadénite</term><term>Maladies pulmonaires</term><term>Mâle</term><term>Radiographie</term><term>Sarcoïdose</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Efficacy of treatment, including its immediate and longterm outcomes, in 109 patients with atypical respiratory sarcoidosis were analysed. The treatment regimens were as follows: corticosteroid hormones supplemented by delagil and vitamin E, intermittent corticosteroid therapy, administration of long-acting++ corticosteroid hormones and treatment with presocyl, delagil and vitamin E. Due to the given treatment, a favourable clinical effect was achieved in 74.3% of the cases with the process remaining stable in 2.8% and recurrent development of the disease in 22.9%. Persistent favourable outcomes in a distant future were registered in 82.9%, stable process--in 3.9%, and progression with aggravation and relapses--in 13.2% of the patients.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2084689</PMID><DateCompleted><Year>1991</Year><Month>05</Month><Day>13</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0032-9533</ISSN><JournalIssue CitedMedium="Print"><Issue>12</Issue><PubDate><Year>1990</Year></PubDate></JournalIssue><Title>Problemy tuberkuleza</Title><ISOAbbreviation>Probl Tuberk</ISOAbbreviation></Journal><ArticleTitle>[Results of the treatment of patients with atypical sarcoidosis of the respiratory organs].</ArticleTitle><Pagination><MedlinePgn>30-3</MedlinePgn></Pagination><Abstract><AbstractText>Efficacy of treatment, including its immediate and longterm outcomes, in 109 patients with atypical respiratory sarcoidosis were analysed. The treatment regimens were as follows: corticosteroid hormones supplemented by delagil and vitamin E, intermittent corticosteroid therapy, administration of long-acting++ corticosteroid hormones and treatment with presocyl, delagil and vitamin E. Due to the given treatment, a favourable clinical effect was achieved in 74.3% of the cases with the process remaining stable in 2.8% and recurrent development of the disease in 22.9%. Persistent favourable outcomes in a distant future were registered in 82.9%, stable process--in 3.9%, and progression with aggravation and relapses--in 13.2% of the patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Teriaeva</LastName><ForeName>M V</ForeName><Initials>MV</Initials></Author></AuthorList><Language>rus</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Rezul'taty lecheniia bol'nykh s atipichnym sarkoidozom organov dykhaniia.</VernacularTitle></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Probl Tuberk</MedlineTA><NlmUniqueID>0414141</NlmUniqueID><ISSNLinking>0032-9533</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>1406-18-4</RegistryNumber><NameOfSubstance UI="D014810">Vitamin E</NameOfSubstance></Chemical><Chemical><RegistryNumber>6E17K3343P</RegistryNumber><NameOfSubstance UI="C023676">chloroquine diphosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>886U3H6UFF</RegistryNumber><NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9PHQ9Y1OLM</RegistryNumber><NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008171" MajorTopicYN="N">Lung Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008199" MajorTopicYN="N">Lymphadenitis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011239" MajorTopicYN="N">Prednisolone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011859" MajorTopicYN="N">Radiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012507" MajorTopicYN="N">Sarcoidosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014810" MajorTopicYN="N">Vitamin E</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2084689</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Teriaeva, M V" sort="Teriaeva, M V" uniqKey="Teriaeva M" first="M V" last="Teriaeva">M V Teriaeva</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000141 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000141 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:2084689
|texte= [Results of the treatment of patients with atypical sarcoidosis of the respiratory organs].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:2084689" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |